Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen : an international collaboration
dc.contributor.author | Rhee, Soo-Yon | en_ZA |
dc.contributor.author | Varghese, Vici | en_ZA |
dc.contributor.author | Holmes, Susan P. | en_ZA |
dc.contributor.author | Van Zyl, Gert U. | en_ZA |
dc.contributor.author | Steegen, Kim | en_ZA |
dc.contributor.author | Boyd, Mark A. | en_ZA |
dc.contributor.author | Cooper, David A. | en_ZA |
dc.contributor.author | Nsanzimana, Sabin | en_ZA |
dc.contributor.author | Saravanan, Shanmugam | en_ZA |
dc.contributor.author | Charpentier, Charlotte | en_ZA |
dc.contributor.author | De Oliveira, Tulio | en_ZA |
dc.contributor.author | Etiebet, Mary-Ann A. | en_ZA |
dc.contributor.author | Garcia, Federico | en_ZA |
dc.contributor.author | Goedhals, Dominique | en_ZA |
dc.contributor.author | Gomes, Perpetua | en_ZA |
dc.contributor.author | Gunthard, Huldrych F. | en_ZA |
dc.contributor.author | Hamers, Raph L. | en_ZA |
dc.contributor.author | Hoffmann, Christopher J. | en_ZA |
dc.contributor.author | Hunt, Gillian | en_ZA |
dc.contributor.author | Jiamsakul, Awachana | en_ZA |
dc.contributor.author | Kaleebu, Pontiano | en_ZA |
dc.contributor.author | Kanki, Phyllis | en_ZA |
dc.contributor.author | Kantor, Rami | en_ZA |
dc.contributor.author | Kerschberger, Bernhard | en_ZA |
dc.contributor.author | Marconi, Vincent C. | en_ZA |
dc.contributor.author | Ndahimana, Jean D'amour | en_ZA |
dc.contributor.author | Ndembi, Nicaise | en_ZA |
dc.contributor.author | Ngo-Giang-Huong, Nicole | en_ZA |
dc.contributor.author | Rokx, Casper | en_ZA |
dc.contributor.author | Santoro, Maria M. | en_ZA |
dc.contributor.author | Schapiro, Jonathan M. | en_ZA |
dc.contributor.author | Schmidt, Daniel | en_ZA |
dc.contributor.author | Seu, Lillian | en_ZA |
dc.contributor.author | Sigaloff, Kim C. E. | en_ZA |
dc.contributor.author | Sirivichayakul, Sunee | en_ZA |
dc.contributor.author | Skhosana, Lindiwe | en_ZA |
dc.contributor.author | Sunpath, Henry | en_ZA |
dc.contributor.author | Tang, Michele | en_ZA |
dc.contributor.author | Yang, Chunfu | en_ZA |
dc.contributor.author | Carmona, Sergio | en_ZA |
dc.contributor.author | Gupta, Ravindra K. | en_ZA |
dc.contributor.author | Shafer, Robert W. | en_ZA |
dc.date.accessioned | 2018-08-17T08:47:18Z | |
dc.date.available | 2018-08-17T08:47:18Z | |
dc.date.issued | 2017 | |
dc.description | CITATION: Rhee, S. Y., et al. 2017. Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen : an international collaboration. EBioMedicine, 18: 225-235, doi:10.1016/j.ebiom.2017.03.024. | |
dc.description | The original publication is available at https://www.sciencedirect.com | |
dc.description.abstract | Tenofovir disoproxil fumarate (TDF) genotypic resistance defined by K65R/N and/or K70E/Q/G occurs in 20% to 60% of individuals with virological failure (VF) on a WHO-recommended TDF-containing first-line regimen. However, the full spectrum of reverse transcriptase (RT) mutations selected in individuals with VF on such a regimen is not known. To identify TDF regimen-associated mutations (TRAMs), we compared the proportion of each RT mutation in 2873 individuals with VF on a WHO-recommended first-line TDF-containing regimen to its proportion in a cohort of 50,803 antiretroviral-naïve individuals. To identify TRAMs specifically associated with TDF-selection pressure, we compared the proportion of each TRAM to its proportion in a cohort of 5805 individuals with VF on a first-line thymidine analog-containing regimen. We identified 83 TRAMs including 33 NRTI-associated, 40 NNRTI-associated, and 10 uncommon mutations of uncertain provenance. Of the 33 NRTI-associated TRAMs, 12 – A62V, K65R/N, S68G/N/D, K70E/Q/T, L74I, V75L, and Y115F – were more common among individuals receiving a first-line TDF-containing compared to a first-line thymidine analog-containing regimen. These 12 TDF-selected TRAMs will be important for monitoring TDF-associated transmitted drug-resistance and for determining the extent of reduced TDF susceptibility in individuals with VF on a TDF-containing regimen. | en_ZA |
dc.description.uri | https://www.sciencedirect.com/science/article/pii/S2352396417301202?via%3Dihub | |
dc.description.version | Publisher's version | |
dc.format.extent | 11 pages | |
dc.identifier.citation | Rhee, S. Y., et al. 2017. Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen : an international collaboration. EBioMedicine, 18: 225-235, doi:10.1016/j.ebiom.2017.03.024 | |
dc.identifier.issn | 2352-3964 (online) | |
dc.identifier.other | doi:10.1016/j.ebiom.2017.03.024 | |
dc.identifier.other | doi:10.1016/j.ebiom.2017.03.024 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/104277 | |
dc.language.iso | en_ZA | en_ZA |
dc.publisher | Elsevier | |
dc.rights.holder | Authors retain copyright | |
dc.subject | Highly active antiretroviral therapy | en_ZA |
dc.subject | Reverse transcriptase | en_ZA |
dc.title | Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen : an international collaboration | en_ZA |
dc.type | Article | en_ZA |